Nusayba Bagegni

4PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|Mar 21, 2025
Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.

Foluso O Ademuyiwa, Cynthia X Ma, Katherine Weilbaecher

|Jun 02, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.

Whitney L Hensing, Lorenzo Gerratana, Katherine Clifton

|May 06, 2022
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.

Nusayba A Bagegni, Andrew A Davis, Katherine K Clifton

Pageof 1

Frequent Collaborators

2 joint publications

Andrew Davis

2 joint publications

Katherine Clifton

2 joint publications

Cynthia X Ma

2 joint publications

Ron Bose